2019 American Transplant Congress
TORC1 Inhibition In Vitro and in a Humanized Mouse Model Protects Activated Human Regulatory T Cells from Self-Inflicted Damage via Granzyme B
Transplantation Research Center, BWH/Harvard Medical School, Boston, MA
*Purpose: Optimizing Regulatory T cells (Tregs) survival is of utmost importance to maximize the efficacy of utilizing them in adoptive cell therapy. We previously described…2019 American Transplant Congress
Inhibition of mTORC2 Causes Hyper Phosphorylation of ERK Induced by Co-Ligation of HLA-I and II Antibody
*Purpose: Transplant recipients developing donor specific antibodies (DSA) are at risk for antibody-mediated rejection (AMR). It has been reported that as many as 30% of…2019 American Transplant Congress
Allogenic Islets Cure Diabetes Following Transplantation in Omental Pouch in a Non-Human Primate Model
*Purpose: In the current standard clinical transplant approach, islet cells are administered intravenously into the portal system where they lodge in the liver. This approach…2019 American Transplant Congress
Use of mTOR Inhibitors in Hypersensitized Kidney Transplant Recipients: Breaking False Myths
*Purpose: Many centers avoid the use of mTOR inhibitors (mTORi) in hypersensitized kidney transplant recipients and usually employ an immunosuppression based on Mycophenolic Acid (MPA),…2018 American Transplant Congress
Glycolytic Bias in mTORC2-Deficient Dendritic Cells Potentiates Antigen-Specific Immunity and Accelerates Graft Rejection
The mechanistic target of rapamycin (mTOR) is known to function in two complexes: mTOR complex 1 (mTORC1) and mTORC2. While the function of mTORC1 in…2018 American Transplant Congress
Rapamycin Impairs Human Endothelial Cell Alloimmunogenicity Independent of PD-1/PD-1 Ligand Inhibitory Signaling
Department of Surgery, Duke University Medical Center, Durham, NC.
Rapamycin prevents costimulation blockade (CoB)-resistant rejection in mice and primates, and early human data suggests a similar salutary effect. We have hypothesized that one mechanism…2018 American Transplant Congress
B Cell Reconstitution: 36-Month Analysis of Patients Post-Alemtuzumab Induction Followed by Belatacept-Based Immunosuppression
Alemtuzumab induction combined with belatacept and rapamycin (ABR) maintenance immunotherapy effectively prevents costimulation blockade resistant rejection (CoBRR). We longitudinally investigated kinetics of repopulating B cell…2018 American Transplant Congress
Emergence of a Costimulation-Susceptible T Cell Repertoire Post-Alemtuzumab Induction
Kidney transplant patients treated with belatacept-based regimens without depletional induction have higher rates of costimulation blockade resistant rejection (CoBRR). In contrast, belatacept effectively prevents rejection…2018 American Transplant Congress
TORC1 Inhibition Protects Activated Human Regulatory T Cells from Self-Inflicted Damage via Granzyme B
Transplantation Research Center, BWH, Harvard Medical School, Boston, MA.
The safety and efficacy of adoptive transfer of regulatory T cells (Tregs) are being extensively investigated in ongoing clinical trials. However, these trials have been…2018 American Transplant Congress
Lymph Node Reprogramming: Microparticle Delivery of Immune Signals to Induce Tolerance and Prolong Allograft Survival
Introduction: Microparticle (MP) loaded with peptide antigen plus other immune signals and delivered directly into lymph nodes (LN) can result in either pro-inflammatory or anti-inflammatory…
- « Previous Page
- 1
- 2
- 3
- 4
- …
- 6
- Next Page »